期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

茚地那韦尿路结石 被引量：2

Indinavir urolithiasis
下载PDF
导出
摘要 茚地那韦属于蛋白酶抑制剂 ,是一种抗病毒药物 ,已用于治疗HIV感染及获得性免疫缺陷综合征 (AIDS)病人。同其他蛋白酶抑制剂相比 ,茚地那韦形成尿路结石的危险最大。本文综述了茚地那韦尿路结石的发病率、形成机制、诊断与治疗方法 ,并对如何预防茚地那韦尿路结石提出了建议。 Indinavir is a protease inhibitor that has been found to be extremely effective for patients with HIV and acquired immunodeficiency syndrome (AIDS). However,of all protease inhibitors currently in use,indinavir is associated with the greatest risk for the development of urolithiasis. We review the incidence,mechanism of formation,diagnosis and treatment of indinavir urolithiasis,and suggest how to prevent stone formation.
作者 谷现恩
机构地区 北京市垂杨柳医院泌尿外科
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2004年第7期444-446,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 尿路结石 HIV 获得性免疫缺陷综合征 茚地那韦 urolithiasis HIV acquired immunodeficiency syndrome indinavir
分类号 R978.7 [医药卫生—药品] R691.4 [医药卫生—泌尿科学]
  • 相关文献

参考文献15

  • 1[1]STEIN DS, FISH DG, BILELLO JA, et al. A 24 - week open - label phase Ⅰ/Ⅱ evaluation of the HIV protease inhibitor MK639(indinavir) [J]. AIDS, 1996, 10(5) :485-492.
  • 2[2]WU DS, STOLLER ML. Indinavir urolithiasis [ J ]. Curr Opin Urol, 2000, 10(6) :557-561.
  • 3[3]SALTEL E, ANGEL JB, FUTTER NG, et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis[J]. J Urol, 2000, 164(6) :1895-1897.
  • 4[4]REITER WJ,SCHON-PERNERSTORFER H,DORFINGER K,et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed[J]. J Urol, 1999,161(4): 1082-1084.
  • 5[5]GRASES F, COSTA-BAUZA A, GARCIA-GONZALEZ R, et al.Indinavir crystallization and urolithiasis [J]. Int Urol Nephrol,1999,31(1) :23-29.
  • 6[6]HERMIEU J,PREVOT M,RAVERY V,et al. Urolithiasis and the protease inhibitor indinavir[J ]. Eur Urol, 1999,35 ( 3 ): 239-241.
  • 7[7]DAUDON M, ESTEPA L, VIARD JP, et al. Urinary stones in HIV-positive patients treated with indinavir [J]. Lancet, 1997,349(9061) : 1294-1295.
  • 8[8]GENTLE DL, STOLLER ML, JARRETT TW,et al. Protease inhibitor-induced urolithiasis [J]. Urology, 1997, 50 ( 4 ): 508-511.
  • 9[9]KOPP JB, MILLER KL, MICAN JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir[J]. Ann Intern Med, 1997, 127(2): 119-125.
  • 10[10]KOHAN AD, ARMENAKAS NA, FRACCHIA JA. Indinavir urolithiasis:an emerging cause of renal colic in patients with human immunodeficiency virus[J]. J Urol, 1999,161(6): 1765-1768.

同被引文献24

  • 1李珂珂,王丽丽,綦跃花,刘呈华,魏传梅.头孢菌素类抗生素与葡萄糖酸钙体外配伍试验[J].滨州医学院学报,2004,27(6):454-455. 被引量：6
  • 2崔银珠.引发肾结石的药物[J].世界临床药物,2005,26(4):237-243. 被引量：7
  • 3Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet, 1988,2 : 1411-1413.
  • 4Cachat P, Cochat N, Jouvenet M, et al. Ceftfiaxone-associated iaephrolithiasis. Nephrol Dial Transplant, 1990,5 : 974-976.
  • 5Dusseault BN, Croce KJ, Pais VM Jr. Radiographic characteristics of sulfadiazine urolithiasis. Urology, 2009,73 : 928.e5-e6.
  • 6Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology, 1991,100:1665-1670.
  • 7Prince JS, Senac MO Jr. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child. Pediatr Radiol, 2003, 33 : 648-651.
  • 8Biner B, Oner N, Celtik C, et al. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound, 2006, 34 : 217-222.
  • 9Mohkam M, Karimi A, Gharib A, et al. Ceftriaxone associated nephrelithiasis: a prospective study in 284 children. Pediatr Nephrol, 2007,22 : 690-694.
  • 10杨帆,熊曾,高雅军,雷光武.含三聚氰胺问题奶粉致泌尿系结石影像表现[J].放射学实践,2009,24(5):491-494. 被引量：4

引证文献2

二级引证文献5

中国新药与临床杂志
2004年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部